PMID- 8914867
OWN - NLM
STAT- MEDLINE
DCOM- 19970508
LR  - 20190914
IS  - 0143-4179 (Print)
IS  - 0143-4179 (Linking)
VI  - 30
IP  - 4
DP  - 1996 Aug
TI  - Effects of neuropeptide Y (NPY) and [D-Trp32]NPY on monoamine and metabolite 
      levels in dialysates from rat hypothalamus during feeding behavior.
PG  - 391-8
AB  - Administration of neuropeptide Y (NPY) into hypothalamic areas or into the 
      cerebral ventricles induces marked increases in food consumption in satiated 
      rats. Since monoamines have been suggested to be involved in NPY-induced feeding, 
      we investigated the effects of NPY and [D-Trp32]NPY, a putative NPY antagonist, 
      on extracellular levels of norepinephrine (NE), dopamine (DA), serotonin (5-HT), 
      3,4-dihydroxyphenyl acetic acid (DOPAC), homovanillic acid (HVA) and 
      5-hydroxyindole-3-acetic acid (5-HIAA) in the hypothalamus, including the 
      paraventricular hypothalamic nuclei (PVN), during feeding behavior. 
      Intracerebroventricular (i.c.v.) injections of NPY (20 microg) significantly 
      increased extracellular NE (1.5-fold), DA (2.5-fold), DOPAC (2-fold) and HVA 
      (3-fold), and did not change 5-HT or 5-HIAA levels. This dose of NPY 
      significantly increased food intake over a 2 h period. The putative NPY 
      antagonist [D-Trp32]NPY (40 microg, i.c.v.) produced similar neurochemical 
      changes to NPY: it increased dialysate levels of NE (1.7-fold), DA (2.5-fold), 
      DOPAC (1.6-fold) and HVA (2.2-fold) and did not change 5-HT or 5-HIAA levels. 
      [D-Trp32]NPY also produced a significant increase in food intake. I.c.v. 
      administration of [D-Trp32]NPY 5 min before NPY did not significantly change the 
      increase in NE, DA, HVA and DOPAC induced by NPY. In these animals, food 
      consumption was also significantly increased. These data indicate that 
      NPY-induced feeding is associated with activation of the hypothalamic 
      monoaminergic system and that [D-Trp32]NPY, at the dose given, acts as an agonist 
      and not as an antagonist at NPY receptors in vivo.
FAU - Matos, F F
AU  - Matos FF
AD  - CNS Drug Discovery, Bristol-Myers Squibb Pharmaceutical Research Institute, 
      Wallingford, CT 06492, USA.
FAU - Guss, V
AU  - Guss V
FAU - Korpinen, C
AU  - Korpinen C
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Neuropeptides
JT  - Neuropeptides
JID - 8103156
RN  - 0 (Biogenic Monoamines)
RN  - 0 (Neuropeptide Y)
RN  - 102-32-9 (3,4-Dihydroxyphenylacetic Acid)
RN  - 153549-78-1 (neuropeptide Y, Trp(32)-)
RN  - 333DO1RDJY (Serotonin)
RN  - 54-16-0 (Hydroxyindoleacetic Acid)
RN  - VTD58H1Z2X (Dopamine)
RN  - X4W3ENH1CV (Norepinephrine)
RN  - X77S6GMS36 (Homovanillic Acid)
SB  - IM
MH  - 3,4-Dihydroxyphenylacetic Acid/metabolism
MH  - Analysis of Variance
MH  - Animals
MH  - Biogenic Monoamines/*metabolism
MH  - Dopamine/metabolism
MH  - Feeding Behavior/*drug effects
MH  - Homovanillic Acid/metabolism
MH  - Hydroxyindoleacetic Acid/metabolism
MH  - Hypothalamus/*drug effects/metabolism
MH  - Male
MH  - Microdialysis
MH  - Neuropeptide Y/*analogs & derivatives/*pharmacology
MH  - Norepinephrine/metabolism
MH  - Rats
MH  - Rats, Wistar
MH  - Serotonin/metabolism
EDAT- 1996/08/01 00:00
MHDA- 1996/08/01 00:01
CRDT- 1996/08/01 00:00
PHST- 1996/08/01 00:00 [pubmed]
PHST- 1996/08/01 00:01 [medline]
PHST- 1996/08/01 00:00 [entrez]
AID - S0143-4179(96)90030-X [pii]
AID - 10.1016/s0143-4179(96)90030-x [doi]
PST - ppublish
SO  - Neuropeptides. 1996 Aug;30(4):391-8. doi: 10.1016/s0143-4179(96)90030-x.